Capitalizing on Known Therapeutic Benefits of Unsaturated Fatty Acids in
LONDON, October 10 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it has initiated a cardiovascular development strategy to capitalize on the known therapeutic benefits of unsaturated fatty acids in cardiovascular disease. Amarin plans to utilize its extensive know-how and experience in lipid science to develop a series of products targeting the vascular system, endothelial dysfunction and vascular re-modeling.
Dr. Declan Doogan, Amarin's President of Research and Development commented "Building on an extensive knowledge base in cardiovascular disease, we plan to leverage our expertise in lipid science to create new therapies from our existing family of compounds. We are fortunate to have the know-how, the resources and the ability to draw on an extensive knowledge network in cardiovascular disease."
Rick Stewart, Chief Executive Officer, commented "While neurology remains Amarin's core focus, the new cardiovascular strategy capitalizes on existing assets which already have an established safety and efficacy profile in Japan. Consequently, this is a logical extension from Amarin's existing therapeutic base for ultra-pure EPA and its derivatives. The expansion of Amarin's therapeutic reach into diseases with a significantly greater prevalence than neurological disease enhances our development portfolio mix and creates added value from our lipid technology platform."
Amarin intends to commence a series of clinical trials with AMR 101
(97% pure EPA) in dyslipidemia, the first of which will commence by the end
of this year. In addition, Am
|SOURCE Amarin Corporation Plc|
Copyright©2007 PR Newswire.
All rights reserved